- ISIN
- US1523091007
- CUSIP
- 152309100
- Delisting Date
- Jun 25, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 28, 2021
Highlights
- EPS (TTM)
- -$1.81
- Total Revenue (TTM)
- $15.00M
- Gross Profit (TTM)
- $15.00M
- EBITDA (TTM)
- -$227.27M
- Year Range
- $13.22 - $40.56
- Target Price
- $38.60
- ROA (TTM)
- -35.30%
- ROE (TTM)
- -46.06%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CNTA Performance Chart
Loading charts...
Compare this symbol against anything
Returns By Period
Centessa Pharmaceuticals Limited
- 1D
- —
- 1M
- —
- 6M
- —
- YTD
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
CNTA Monthly Returns History
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.76% | 9.32% | 47.88% | -0.76% | 0.86% | 1.86% | 61.94% | ||||||
| 2025 | 1.01% | -8.10% | -7.52% | -4.66% | -1.46% | -2.74% | 30.67% | -2.21% | 44.43% | 2.68% | 16.59% | -13.85% | 49.31% |
| 2024 | 2.89% | 28.33% | 7.52% | -18.94% | -5.79% | 4.63% | 16.61% | 28.21% | 18.44% | -5.94% | 19.08% | -6.48% | 110.43% |
| 2023 | 29.03% | -12.00% | 9.38% | 22.60% | -4.45% | 37.25% | 27.63% | -4.56% | -14.19% | 1.55% | -8.68% | 32.67% | 156.77% |
| 2022 | -15.36% | -6.40% | 0.56% | -2.79% | -48.39% | 8.22% | -11.29% | 0.69% | -7.59% | -1.24% | 0.76% | -22.50% | -72.47% |
| 2021 | 7.41% | 2.11% | -7.07% | 6.83% | -24.26% | 2.99% | -31.10% | -4.98% | -44.40% |
Benchmark Metrics
Centessa Pharmaceuticals Limited has an annualized alpha of 30.21%, beta of 1.02, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since May 28, 2021.
- This stock captured 189.85% of S&P 500 Index gains and 156.36% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 30.21%
- Beta
- 1.02
- R²
- 0.06
- Upside Capture
- 189.85%
- Downside Capture
- 156.36%
Return for Risk
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Centessa Pharmaceuticals Limited (CNTA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CNTA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | — | — | |
| Sortino ratioReturn per unit of downside risk | — | — | |
| Omega ratioGain probability vs. loss probability | — | 1.25 | — |
| Calmar ratioReturn relative to maximum drawdown | — | 2.00 | — |
| Martin ratioReturn relative to average drawdown | — | 8.49 | — |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Centessa Pharmaceuticals Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Centessa Pharmaceuticals Limited was 88.19%, occurring on Feb 16, 2023. Recovery took 687 trading sessions.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-88.19%Feb 2023 | 1y 8mo | 2y 9mo | 4y 4moJun 2021 - Nov 2025 | — |
-26.38%Jan 2026 | 1mo 5d | 2mo 18d | 3mo 23dDec 2025 - Mar 2026 | — |
-13.54%Jun 2021 | 8d | 6d | 14dJun 2021 - Jun 2021 | — |
-3.06%Dec 2025 | 6d | 3d | 9dNov 2025 - Dec 2025 | — |
-2.89%Nov 2025 | 1d | 4d | 5dNov 2025 - Nov 2025 | — |
Drawdown Indicators
| CNTA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | — | -56.78% | — |
Max Drawdown (1Y)Largest decline over 1 year | — | -9.10% | — |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | — | -1.58% | — |
Average DrawdownAverage peak-to-trough decline | — | -10.70% | — |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 2.14% | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Centessa Pharmaceuticals Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Centessa Pharmaceuticals Limited is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CNTA relative to other companies in the Biotechnology industry. Currently, CNTA has a P/S ratio of 362.2. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CNTA
Add Centessa Pharmaceuticals Limited to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CNTA